InChI=1S/C51H69N7O7/c1- 32(2) 27- 39- 48(63) 58- 26- 25- 34(5) 43(58) 49(64) 57(9) 41(28- 33(3) 4) 46(61) 55- 51(6,7) 50(65) 54- 40(30- 36- 21- 15- 11- 16- 22- 36) 47(62) 56(8) 42(31- 37- 23- 17- 12- 18- 24- 37) 45(60) 52- 38(44(59) 53- 39) 29- 35- 19- 13- 10- 14- 20- 35/h10- 24,32- 34,38- 43H,25- 31H2,1- 9H3,(H,52,60) (H,53,59) (H,54,65) (H,55,61) /t34- ,38- ,39- ,40- ,41- ,42- ,43- /m0/s1 |
BZXAVUYDKXXNPV-DKTNFYNISA-N |
[H] [C@@] 12[C@@H] (C) CCN1C(=O) [C@H] (CC(C) C) NC(=O) [C@H] (Cc1ccccc1) NC(=O) [C@H] (Cc1ccccc1) N(C) C(=O) [C@H] (Cc1ccccc1) NC(=O) C(C) (C) NC(=O) [C@H] (CC(C) C) N(C) C2=O |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
cyclo[2- methyl- D- alanyl- L- phenylalanyl- N- methyl- L- phenylalanyl- L- phenylalanyl- L- leucyl- (3S)- 3- methyl- L- prolyl- N- methyl- L- leucyl]
|
(3S,9S,12S,15S,18S,23S,23aS)- 9,12,15- tribenzyl- 2,6,6,11,23- pentamethyl- 3,18- bis(2- methylpropyl)hexadecahydro- 1H- pyrrolo[1,2- a][1,4,7,10,13,16,19]heptaazacyclohenicosine- 1,4,7,10,13,16,19- heptone
|
IUPAC
|
9686009
|
Reaxys Registry Number
|
Reaxys
|
14604342
|
PubMed citation
|
Europe PMC
|
|